ClinicalTrials.gg

Program

elecoglipron

Also written as “Elecoglipron”, “AZD5004” and “ECC5004”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Obesity · Heart Failure · Renal Insufficiency, Chronic · Renal Insufficiency, led by 2 companies.

Furthest: phase 3, since Jun 18, 202626 company-led studies, 11 open or runningNext primary completion: Nov 18, 2026 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca2211 open or runningphase 3since Jun 18, 2026Aug 13, 2024Nov 18, 2026phase 1 · NCT07723833
Eccogene40 open or runningphase 1since Dec 8, 2022Dec 8, 2022none ahead
  • Named in AstraZeneca’s own pipeline as elecoglipron, phase 3, as of Oct 30, 2026 (source).

Also a collaborator on its studies: parexel and quotient-sciences.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 4 studies since Dec 8, 2022.

  1. Aug 28, 20242 phase 2 studiesAstraZeneca · NCT06579105, NCT06579092
  2. Oct 29, 2024Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT06703658 · 35 enrolled · Japan
  3. Dec 16, 20242 phase 1 studiesAstraZeneca · NCT06742762, NCT06813781
  4. Feb 27, 2025Phase 1 study in Healthy ParticipantsAstraZeneca · NCT06857695 · 8 enrolled · United Kingdom
  5. Apr 28, 2025Phase 1 study in ObesityAstraZeneca · NCT06948747 · 49 enrolled · United States
  6. May 16, 2025Phase 1 study in ObesityEccogene · NCT06988553 · 45 enrolled · China
  7. May 21, 2025Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT06996886 · 16 enrolled · United States
  8. Feb 26, 2026Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07444424 · 32 enrolled · Japan
  9. Mar 3, 2026Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07455825 · 65 enrolled · United States
  10. Apr 10, 2026Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07534592 · 48 enrolled · United States
  11. Jun 18, 20266 phase 3 studiesPhase 3 reachedAstraZeneca · NCT07664553, NCT07662213, NCT07662135 and 3 more
  12. Jul 20, 2026Phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07723833 · 152 planned · United States
  13. Aug 3, 20263 phase 3 studiesAstraZeneca · NCT07761117, NCT07753993, NCT07775404
  14. Oct 1, 2026Primary completion moved from 2027-06-04 to 2028-04-06Date moved laterphase 3 · +10 months · NCT07775404

Ahead

  1. Nov 18, 2026Primary completion: phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07723833
  2. Jan 25, 2027Primary completion: phase 1 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07534592
  3. Apr 6, 2028Primary completion: phase 3 study in ObesityAstraZeneca · NCT07775404
  4. May 23, 2028Primary completion: phase 3 study in Diabetes Mellitus, Type 2AstraZeneca · NCT07664553

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 26 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07775404Obesity · China, Hong Kong, Malaysia and more3RecruitingAstraZenecaApr 6, 2028351
NCT07753993Renal Insufficiency, Chronic · United States, Argentina, Australia and more3RecruitingAstraZenecaOct 4, 20307,000
NCT07761117Heart Failure · United States, Argentina, Australia and more3RecruitingAstraZenecaSep 3, 20296,950
NCT07723833Diabetes Mellitus, Type 2 · United States1RecruitingAstraZenecaNov 18, 2026152
NCT07667803Weight Management · United States, Argentina, Australia and more3RecruitingAstraZenecaJul 31, 20284,500
NCT07664553Diabetes Mellitus, Type 2 · United States, Australia, Bulgaria and more3RecruitingAstraZenecaMay 23, 2028600
NCT07662213Diabetes Mellitus, Type 2 · United States, Argentina, Australia and more3RecruitingAstraZenecaMay 23, 20281,200
NCT07662135Diabetes Mellitus, Type 2 · United States, Bulgaria, China and more3RecruitingAstraZenecaJul 13, 2028900
NCT07662109Diabetes Mellitus, Type 2 · United States, Argentina, Brazil and more3RecruitingAstraZenecaJul 5, 20282,000
NCT07662044Diabetes Mellitus, Type 2 · United States, Argentina, China and more3RecruitingAstraZenecaJul 14, 2028800
NCT07534592Diabetes Mellitus, Type 2 · United States1Active, not recruitingAstraZenecaJan 25, 202748
NCT07455825Diabetes Mellitus, Type 2 · United States1CompletedAstraZenecaJun 1, 202665
NCT07444424Diabetes Mellitus, Type 2 · Japan1CompletedAstraZenecaJul 2, 202632
NCT06996886Diabetes Mellitus, Type 2 · United States1CompletedAstraZenecaJul 15, 202516
NCT06988553Obesity · China1CompletedEccogeneNov 28, 202545
NCT06948747Obesity · United States1CompletedAstraZenecaOct 3, 202549
NCT06857695Healthy Participants · United Kingdom1CompletedAstraZenecaMay 5, 20258
NCT06813781Hepatic Impairment · United States1CompletedAstraZenecaOct 2, 202533
NCT06742762Renal Insufficiency · United States1CompletedAstraZenecaApr 20, 202516
NCT06703658Diabetes Mellitus, Type 2 · Japan1CompletedAstraZenecaMar 13, 202535
NCT06579105Diabetes Mellitus, Type 2 · United States, Canada, Germany and more2CompletedAstraZenecaDec 19, 2025406
NCT06579092Obesity · United States, Australia, Canada and more2CompletedAstraZenecaNov 21, 2025310
NCT06555822Obesity · United States1CompletedAstraZenecaMar 6, 202531
NCT06293742Diabetes Mellitus, Type 2 · United States1CompletedEccogeneApr 15, 202448
NCT06268145Diabetes Mellitus, Type 2 · United States1CompletedEccogeneMar 29, 202414
NCT05654831Diabetes Mellitus, Type 2 · United States1CompletedEccogeneNov 1, 202369

How it is read

Names in the registry

  • “Elecoglipron”, 10 entries
  • “AZD5004”, 10 entries
  • “ECC5004”, 3 entries
  • “Elecoglipron Reference Formulation Dose A”, 1 entry
  • “Elecoglipron Reference Formulation Dose B”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.